[1] Ballon J S,Pajvani U,Freyberg Z,et al. Molecular pathophysiology of metabolic effects of antipsychotic medications[J]. Trends Endocrinol Metab,2014,25(11):593
[2] Li N,Cao T,Wu X,et al. Progress in genetic polymorphisms related to lipid disturbances induced by atypical antipsychotic drugs[J].Front Pharmacol,2020,10:1669
[3] Grajales D,Ferreira V,Valverde ?魣 M. Second-generation antipsychotics and dysregulation of glucose metabolism:beyond weight gain[J]. Cells,2019,8(11):1336
[4] Li S,Xu C,Tian Y,et al. TOX and ADIPOQ gene polymorphisms are associated with antipsychotic-induced weight gain in Han Chinese[J]. Sci Rep,2017,7: 45203
[5] Li S,Gao Y,Lv H,et al. T4 and waist:hip ratio as biomarkers of antipsychotic-induced weight gainin Han Chinese inpatients with schizophrenia[J]. Psychoneuroendocrinology,2018,88: 54
[6] Fountaine R J,Taylor A E,Mancuso J P,et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men[J]. Obesity (Silver Spring),2010,18(8):1646
[7] Perez-Iglesias R,Mata I,Amado J A,et al. Effect of FTO,SH2B1,LEP,and LEPR polymorphisms on weight gain associated with antipsychotic treatment[J]. Clin Psychopharmacol,2010,30(6):661
[8] Benarroch L,Kowalchuk C,Wilson V,et al. Atypical antipsychotics and effects on feeding: from mice to men[J]. Psychopharmacology,2016,233(14):2629
[9] van der Esch CCL,Kloosterboer S M,van der Ende J,et al. Risk factors and pattern of weight gain in youths using antipsychotic drugs[J]. Eur Child Adolesc Psychiatry,2020,8:24
[10] Caleb C L,Steven C Wr,Rong W,et al. The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C[J]. J Clin Invest,2017,127(9): 3402
[11] Endomba F T,Tankeu A T,Nkeck J R,et al. Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain?[J]. Lipids Health Dis,2020,19(1):22
[12] Roerig J L,Steffen K J,Mitchell J E. Atypical antipsychotic-induced weight gain:insights into mechanisms of action[J]. CNS Drugs,2011,
25(12):1035
[13] Klemettil?覿 J P,Kampman O,Solismaa A,et al. Association study of arcuate nucleus neuropeptide Y neuron receptor gene variation and serum NPY levels in clozapine treated patients with schizophrenia[J]. Eur Psychiatry,2017,2(40):13
[14] Wan X Q,Zeng F,Huang X F,et al. Risperidone stimulates food intake and induces body weight gain via the hypothalamic arcuate nucleus 5-HT2c receptor-NPY pathway[J]. CNS Neurosci Ther,2020, 26(5):558
[15] He M,Deng C,Huang X. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain[J]. CNS Drugs,2013,27(6):423
[16] Lian J,De Santis M,He M,et al. Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: the role of histaminergic and NPY pathways[J]. Pharmacol Res,2015,95-96:20
[17] Al Massadi O,López M,Tsch?觟p M,et al. Current understanding of the hypothalamic ghrelin pathways inducing appetite and adiposity[J]. Trends Neurosci,2017,40(3):167
[18] Chen X,Yu Y,Zheng P,et al. Olanzapine increases AMPK-NPY orexigenic signaling by disrupting H1R-GHSR1a interaction in the hypothalamic neurons of mice[J]. Psychoneuroendocrinology,2020,
114:104594
[19] He M,Zhang Q,Deng C,et al. Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in femalerats[J].Psychoneuroendocrinology,2014,42:153
[20] Qin L,Tiwari A K,Zai C C,et al. Regulation of melanocortin-4-receptor(MC4R) expression by SNP rs17066842 is dependent on glucose concentration[J]. Eur Neuropsychopharmacol,2020,37:39
[21] Czerwensky F,Leucht S,Steimer W. Association of the common MC4R rs17782313 polymorphism with antipsychotic-related weight gain[J]. J Clin Psychopharmacol,2013,33(1):74
[22] Lett T A,Wallace T J,Chowdhury N I,et al. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications[J].Mol Psychiatry,2012,17(3):242
[23] Kelesidis T,Kelesidis I,Chou S,et al.Narrative review: the role of leptin in human physiology: emerging clinical applications[J]. Ann Intern Med,2010,152(2):93
[24] Zhang W,Wu Y. Mitogen- and stress-activated protein kinase-1 activation is involved in melanocortin-induced BDNF expression in Neuro2a neuronal cells[J]. Neuroreport,2020,31(14):1007
[25] Müller D J,Chowdhury N I,Zai C C. The pharmacogenetics of antipsychotic-induced adverse events[J]. Curr Opin Psychiatry,2013, 26(2):144
[26] Rojczyk E,Pa?覥asz A,Wiaderkiewicz R. Effect of short and long-term treatment with antipsychotics on orexigenic/anorexigenic neuropeptides expression in the rat hypothalamus[J]. Neuropeptides,2015, 51:31
[27] Potvin S,Zhornitsky S,Stip E. Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis[J]. Can J Psychiatry,2015,60(3 Suppl 2):S26
[28] Chen X,Wang D D,Li Z P. Time-course and dose-effect of metformin on weight in patients with different disease states[J]. Expert Rev Clin Pharmacol,2020,19:1
[29] Meftah A M,Deckler E,Citrome L,et al. New discoveries for an old drug:a review of recent olanzapine research[J]. Postgrad Med,2020,132(1):80
[30] Correll C U,Sikich L,Reeves G,et al.Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness:results from the IMPACT trial[J]. World Psychiatry,2020,
19(1):69
[31] Literati-Nagy Z,Tory K,Literáti-Nagy B,et al. A novel insulin sensitizer drug candidate-BGP-15-can prevent metabolic side effects of atypical antipsychotics[J]. Pathol Oncol Res,2012,18(4):1071
[32] Ratliff J C,Palmese L B,Reutenauer E L,et al. An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes[J]. Clin Schizophr Relat Psychoses,2015,8(4):196
[33] Kim H,Park M,Lee S K,et al. Phosphorylation of hypothalamic AMPK on serine(485/491) related to sustained weight loss by alpha-lipoic acid in mice treated with olanzapine[J]. Psychopharmacology (Berl),2014,231(20):4059